Key topics in Part 1: The Burden of Vaccine- Preventable Disease: Assessing Risk in Older Adults include:
- Accurately assessing the health burden of vaccine-preventable diseases, including RSV, pneumococcal disease, and herpes zoster (shingles) in older adults, and its impact on health disparities and healthcare systems via
- Comprehension of the health burden of vaccine-preventable disease
- Evaluating risk for older adults
Don't miss the opportunity to join this series and learn in person, gaining valuable insights into effectively treating vaccine- preventable diseases. Be sure to take part in part 2 and part 3 to maximize your education and impact!
- Part 2: Impact of Prevention: Updates in Vaccine Development
This activity covers updates on the latest vaccine development and emerging vaccine science and integration of recommended vaccines in clinical workflows - Part 3: Effective Strategies for Improving Vaccine Uptake
This activity covers overcoming barriers in vaccine uptake for older adults
As of October 26, 2024 (after the recording of this activity), the CDC recommends PCV for all “PCV-naive” adults aged 50 years and older. Options include PCV21, PCV210, or PCV15. If PCV15 is used, it needs to be followed 1 year later by a dose of PPSV23.
Speakers
Pamela G. Rockwell, DO
Professor of Family Medicine
University of Michigan Medical School
Ann Arbor, MI, USA
Julio Alberto Ramirez, MD
Chief Scientific Officer
Norton Infectious Diseases Institute, Norton Healthcare
Emeritus Professor of Medicine
Division of Infectious Diseases, University of Louisville
Louisville, KY, USA
Julio Ramirez, MD, FACP is the Chief Scientific Officer at the Norton Infectious Diseases Institute at Norton Healthcare, in Louisville, Kentucky. He is also an Emeritus Professor of Medicine, Divison of Infectious Diseases at the University of Louisville, Louisville, Kentucky, and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
Dr. Ramirez received his medical degree and internal medicine training at La Plata National University School of Medical Science in Argentina. He trained in critical care medicine at the National Institute of Respiratory Diseases and Thoracic Surgery at the University of Chile; completed a residency in internal medicine at Lincoln Medical Center, New York Medical College; and a fellowship in infectious diseases at the University of Louisville School of Medicine. He is board-certified in internal medicine and holds subspecialty certification in infectious diseases.
Dr. Ramirez’s areas of clinical and translational research include community-acquired pneumonia (CAP), influenza, and emerging respiratory pathogens. Dr. Ramirez is directing the research activities of the Norton Infectious Diseases Institute. Dr. Ramirez’s research activities have received funding from the Centers for Disease Control and Prevention (CDC), the Department of Defense (DoD), and the National Institutes of Health (NIH). Dr. Ramirez has more than 300 peer-reviewed publications. He is also a reviewer for several journals including the New England Journal of Medicine and Annals of Internal Medicine. Dr. Ramirez is the Section Editor on pulmonary infections for the evidence-based clinical decision support UpToDate, and is the current president of the International Respiratory Infections Society.
Dr. Ramirez served as a member of the American Thoracic Society (ATS) committee for the development of national guidelines for the management of CAP, and more recently, on the ATS International Task Force guidelines for the management of COVID-19. He also served as a member of the Food and Drug Administration advisory committee for the approval of anti-infective drugs. Dr. Ramirez is the recipient of the 2013 European Respiratory Society Presidential Award in recognition of his outstanding contribution to research in the field of respiratory infections. Dr. Ramirez is the co-chair of the current ATS-IDSA national guidelines committee for the management of CAP.
Accreditation and Disclosure Information
Target Audience
U.S. primary care physicians, NPs, and PAs including those who are community-based, practice in large ACOs; in rural communities; and who serve patients in underserved areas.
Educational Objective
After completing this CE activity, the participant should be better able to:
• Accurately assess the health burden of vaccine- preventable diseases, including RSV, pneumococcal disease, and herpes zoster (shingles) in older adults, and its impact on health disparities and healthcare systems.
Agenda
- Health Burden of Vaccine-Preventable Disease
- Evaluating Risk for Older Adults
- Case Study
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
AAFP CME Credit
The AAFP has reviewed Moving the Needle in Vaccinations of Older Adults | The Burden of Vaccine-Preventable Disease: Assessing Risk in Older Adults and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 06/28/2024 to 06/27/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs
Medical Learning Institute Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until June 27, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour and 0.5 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This educational activity is supported by an independent medical education grant from GSK.
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Pamela G. Rockwell, DO
Professor of Family Medicine
University of Michigan Medical School
Ann Arbor, MI, USA
Pamela G. Rockwell, DO, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Julio Alberto Ramirez, MD
Chief Scientific Officer
Norton Infectious Diseases Institute, Norton Healthcare
Emeritus Professor of Medicine
Division of Infectious Diseases, University of Louisville
Louisville, KY, USA
Julio Alberto Ramirez, MD, has a financial interest/relationship or affiliation in the form of:
Research funding: Pfizer
The following relationships have ended within the last 24 months:
Consultant/Advisor: Paratek (ended 2/24);Pfizer (ended 10/23)
Research funding: Dompe (ended 3/24)
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute Inc. | All Rights Reserved
Resources
SLIDES
Slides
RESOURCES
Overcoming Immunization Barriers
Transcript